- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Illuccix Gets Expanded FDA Approval for Imaging of Metastatic Prostate Cancer
The expanded indication could facilitate improved access to imaging for patients with metastatic prostate cancer who are candidates for radioligand treatment.
The Food and Drug Administration (FDA) has approved an expanded indication for Illuccix® (Telix Pharmaceuticals) that allows use of the gallium GA 68 gozetotide injection preparation kit for PSMA-guided PET imaging of metastatic prostate cancer to help determine whether patients are candidates for radioligand therapy.1
In order for patients to be considered as viable candidates for targeted radioligand treatment, they need to undergo imaging with an approved gallium-based prostate-specific membrane antigen (PSMA) positron emission tomography (PET) agent, according to Telix Pharmaceuticals. The company added that Pluvicto® (Novartis) is currently the only FDA-approved PSMA-directed radioligand treatment.
“As radioligand therapy for prostate cancer becomes more prevalent, it is critical for doctors to understand who may or may not respond to those treatments. There’s no doubt that appropriate selection of patients for PSMA-targeted radioligand therapy is dependent on appropriate imaging,” emphasized Oliver Sartor, M.D., a professor of medicine and the director of the Tulane Cancer Center at the Tulane University School of Medicine in New Orleans.
(Editor’s note: For related content, see “Recurrent Prostate Cancer and Low PSA Levels: Can an Emerging PSMA PET Agent Have an Impact?” and “Could an Emerging PSMA/PET Imaging Agent Improve the Detection of Recurrent Prostate Cancer?”)
Telix Pharmaceuticals said findings from the phase 3 VISION trial demonstrated the ability of Illuccix to aid in the detection of prostate cancer and help identify patients who may benefit from PSMA-based radioligand therapy.
“Ga-68 PSMA-11 PET was used in the VISION trial and, when used in combination with contrast-enhanced CT, represents a powerful tool for detecting prostate cancer and helping guide patient management,” noted Dr. Sartor, the lead author of the VISION study.2
References
1. Telix Pharmaceuticals Limited. FDA approves expanded indication for Telix’s Illuccix® to include patient selection for PSMA-directed radioligand therapy. Cision PR Newswire. Available at: https://www.prnewswire.com/news-releases/fda-approves-expanded-indication-for-telixs-illuccix-to-include-patient-selection-for-psma-directed-radioligand-therapy-301773819.html . Published March 16, 2023. Accessed March 16, 2023.
2. Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385:1091-1103.
Can MRI-Based Deep Learning Improve Risk Stratification in PI-RADS 3 Cases?
January 30th 2025In external validation testing, a deep learning model demonstrated an average AUC of 87.6 percent for detecting clinically significant prostate cancer (csPCA) on prostate MRI for patients with PI-RADS 3 assessments.
Emerging PET Agent Garners Second FDA Fast Track Designation for Prostate Cancer Imaging
January 24th 2025In addition to an August FDA fast track designation for PSMA PET imaging in patients with suspected metastasis, the radiopharmaceutical 64Cu-SAR-bisPSMA has earned another fast track designation for imaging of biochemical recurrence.
Study Examines Prognostic Value of Baseline PSMA PET/CT Factors in Patients with mCRPC
January 24th 2025Doubling of total tumor volume on PSMA PET/CT is 41 percent more likely to reduce overall survival in patients with metastatic castration-resistant prostate cancer (mCRPC), according to new research.
Can Deep Learning Radiomics with bpMRI Bolster Accuracy for Prostate Cancer Prognosis?
January 22nd 2025An emerging deep learning radiomics model based on biparametric MRI (bpMRI) offered a 14 to 17 percent higher AUC range than PI-RADS scoring for predicting the aggressiveness of prostate cancer, according to new research findings.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI-Based AI Enhance Risk Stratification in Prostate Cancer?
January 13th 2025Employing baseline MRI and clinical data, an emerging deep learning model was 32 percent more likely to predict the progression of low-risk prostate cancer (PCa) to clinically significant prostate cancer (csPCa), according to new research.
